drugset / Trial / NCT03791905

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

NCT03791905 ↗

Phase 2 Unknown 216 enrolled Mian XI
RandomizedParallel-groupTriple-blindTreatment

Summary

Since multiple studies have demonstrated that PET can identify responders and non-responders to induction chemotherapy, using FDG-PET imaging to guide treatment decisions has prompted interest in clinical practice. The aim of this study was to evaluate whether changing chemotherapy regimen during radiation based on PET response to induction chemotherapy can improve clinical complete response (cCR) in patients with unresectable esophageal squamous cell carcinoma (ESCC).

Timeline

Start
2019-01-15
Primary completion
2021-07
Completion
2023-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 —
Subject Leucovorin Small molecule 400 mg/m2 —
Subject Oxaliplatin Small molecule 85 mg/m2 —
Subject Paclitaxel Small molecule 150 mg/m2 —
Subject fluorouracil Small molecule 2 g —